Science Confirms Turmeric As Effective As 14 Drugs

Posted on:

Monday, May 13th 2013 at 2:00 pm

Written By:

Sayer Ji, Founder

Turmeric is one the most thoroughly researched plants in existence today.  Its medicinal properties and components (primarily curcumin) have been the subject of over 5600 peer-reviewed and published biomedical studies.  In fact, our five-year long research project on this sacred plant
has revealed over 600 potential preventive and therapeutic
applications, as well as 175 distinct beneficial physiological effects.
This entire database of 1,585 ncbi-hyperlinked turmeric abstracts can be
downloaded as a PDF at our Downloadable Turmeric Document page, and acquired either as a retail item or with 200 GMI-tokens, for those of you who are already are members and receive them automatically each month.

Given
the sheer density of research performed on this remarkable spice, it is
no wonder that a growing number of studies have concluded that it
compares favorably to a variety of conventional medications, including:

• Lipitor/Atorvastatin(cholesterol medication): A 2008 study published in the journal Drugs in R & D found
  that a standardized preparation of curcuminoids from Turmeric compared
  favorably to the drug atorvastatin (trade name Lipitor) on endothelial
  dysfunction, the underlying pathology of the blood vessels that drives
  atherosclerosis, in association with reductions in inflammation and
  oxidative stress in type 2 diabetic patients. [i]  [For addition curcumin and 'high cholesterol' research – 8 abstracts]
• Corticosteroids (steroid medications): A 1999 study published in the journal Phytotherapy Research found
  that the primary polyphenol in turmeric, the saffron colored pigment
  known as curcumin, compared favorably to steroids in the management of
  chronic anterior uveitis, an inflammatory eye disease.[ii]  A 2008 study published in Critical Care Medicine
  found that curcumin compared favorably to the corticosteroid drug
  dexamethasone in the animal model as an alternative therapy for
  protecting lung transplantation-associated injury by down-regulating
  inflammatory genes.[iii] An earlier 2003 study published in Cancer Letters found the same drug also compared favorably to dexamethasone in a lung ischaemia-repurfusion injury model.[iv]  [for additional curcumin and inflammation research – 52 abstracts]
• Prozac/Fluoxetine & Imipramine  (antidepressants): A 2011 study published in the journal Acta Poloniae Pharmaceutica found that curcumin compared favorably to both drugs in reducing depressive behavior in an animal model.[v] [for additional curcumin and depression research – 5 abstracts]
• Aspirin (blood thinner): A 1986 in vitro and ex vivo study published in the journal Arzneimittelforschung
  found that curcumin has anti-platelet and prostacyclin modulating
  effects compared to aspirin, indicating it may have value in patients
  prone to vascular thrombosis and requiring anti-arthritis therapy.[vi]  [for additional curcumin and anti-platelet research]
• Anti-inflammatory Drugs: A 2004 study published in the journal Oncogene found that curcumin (as well as resveratrol) were effective alternatives to the drugs aspirin, ibuprofen, sulindac, phenylbutazone, naproxen, indomethacin, diclofenac, dexamethasone, celecoxib, and tamoxifen in exerting anti-inflammatory and anti-proliferative activity against tumor cells.[vii] [for additional curcumin and anti-proliferative research – 15 abstracts]
• Oxaliplatin (chemotherapy drug): A 2007 study published in the International Journal of Cancer found that curcumin compares favorably with oxaliplatin as an antiproliferative agenet in colorectal cell lines.[viii] [for additional curcumin and colorectal cancer research – 52 abstracts]
• Metformin (diabetes drug): A 2009 study published in the journal Biochemitry and Biophysical Research Community explored
  how curcumin might be valuable in treating diabetes, finding that it
  activates AMPK (which increases glucose uptake) and suppresses
  gluconeogenic gene expression  (which suppresses glucose production in
  the liver) in hepatoma cells. Interestingly, they found curcumin to be
  500 times to 100,000 times (in the form known as
  tetrahydrocurcuminoids(THC)) more potent than metformin in activating
  AMPK and its downstream target acetyl-CoA carboxylase (ACC). [ix]

Posted on:

Monday, May 13th 2013 at 2:00 pm

Written By:

Sayer Ji, Founder

Turmeric is one the most thoroughly researched plants in existence today.  Its medicinal properties and components (primarily curcumin) have been the subject of over 5600 peer-reviewed and published biomedical studies.  In fact, our five-year long research project on this sacred plant
has revealed over 600 potential preventive and therapeutic
applications, as well as 175 distinct beneficial physiological effects.
This entire database of 1,585 ncbi-hyperlinked turmeric abstracts can be
downloaded as a PDF at our Downloadable Turmeric Document page, and acquired either as a retail item or with 200 GMI-tokens, for those of you who are already are members and receive them automatically each month.

Given
the sheer density of research performed on this remarkable spice, it is
no wonder that a growing number of studies have concluded that it
compares favorably to a variety of conventional medications, including:

• Lipitor/Atorvastatin(cholesterol medication): A 2008 study published in the journal Drugs in R & D found
  that a standardized preparation of curcuminoids from Turmeric compared
  favorably to the drug atorvastatin (trade name Lipitor) on endothelial
  dysfunction, the underlying pathology of the blood vessels that drives
  atherosclerosis, in association with reductions in inflammation and
  oxidative stress in type 2 diabetic patients. [i]  [For addition curcumin and 'high cholesterol' research – 8 abstracts]
• Corticosteroids (steroid medications): A 1999 study published in the journal Phytotherapy Research found
  that the primary polyphenol in turmeric, the saffron colored pigment
  known as curcumin, compared favorably to steroids in the management of
  chronic anterior uveitis, an inflammatory eye disease.[ii]  A 2008 study published in Critical Care Medicine
  found that curcumin compared favorably to the corticosteroid drug
  dexamethasone in the animal model as an alternative therapy for
  protecting lung transplantation-associated injury by down-regulating
  inflammatory genes.[iii] An earlier 2003 study published in Cancer Letters found the same drug also compared favorably to dexamethasone in a lung ischaemia-repurfusion injury model.[iv]  [for additional curcumin and inflammation research – 52 abstracts]
• Prozac/Fluoxetine & Imipramine  (antidepressants): A 2011 study published in the journal Acta Poloniae Pharmaceutica found that curcumin compared favorably to both drugs in reducing depressive behavior in an animal model.[v] [for additional curcumin and depression research – 5 abstracts]
• Aspirin (blood thinner): A 1986 in vitro and ex vivo study published in the journal Arzneimittelforschung
  found that curcumin has anti-platelet and prostacyclin modulating
  effects compared to aspirin, indicating it may have value in patients
  prone to vascular thrombosis and requiring anti-arthritis therapy.[vi]  [for additional curcumin and anti-platelet research]
• Anti-inflammatory Drugs: A 2004 study published in the journal Oncogene found that curcumin (as well as resveratrol) were effective alternatives to the drugs aspirin, ibuprofen, sulindac, phenylbutazone, naproxen, indomethacin, diclofenac, dexamethasone, celecoxib, and tamoxifen in exerting anti-inflammatory and anti-proliferative activity against tumor cells.[vii] [for additional curcumin and anti-proliferative research – 15 abstracts]
• Oxaliplatin (chemotherapy drug): A 2007 study published in the International Journal of Cancer found that curcumin compares favorably with oxaliplatin as an antiproliferative agenet in colorectal cell lines.[viii] [for additional curcumin and colorectal cancer research – 52 abstracts]
• Metformin (diabetes drug): A 2009 study published in the journal Biochemitry and Biophysical Research Community explored
  how curcumin might be valuable in treating diabetes, finding that it
  activates AMPK (which increases glucose uptake) and suppresses
  gluconeogenic gene expression  (which suppresses glucose production in
  the liver) in hepatoma cells. Interestingly, they found curcumin to be
  500 times to 100,000 times (in the form known as
  tetrahydrocurcuminoids(THC)) more potent than metformin in activating
  AMPK and its downstream target acetyl-CoA carboxylase (ACC). [ix]